Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 11Gynecologic 5Genitourinary 3Endocrine 3Thoracic 2Tumor-Agnostic 1Sarcoma 1CNS 1

Conditions

Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Hirsutism 2Choristoma 2Adrenal Cortex Neoplasms 2

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mifepristone × Endocrine × Clear all
NCT00936741 2014-04-02

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
30 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT01371565 2014-03-18

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
4 enrolled 7 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT00569582 2013-08-22

SEISMIC

Corcept Therapeutics

Phase 3 Completed
50 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡